Brief: Design Therapeutics Announces Preclinical Data Highlighting Novel Genetac™ Therapy For The Treatment Of Fuchs Endothelial Corneal Dystrophy To Be Presented At ARVO 2022
09/03/2022 11:47
March 9 (Reuters) - Design Therapeutics Inc DSGN.O :
* DESIGN THERAPEUTICS ANNOUNCES PRECLINICAL DATA
HIGHLIGHTING
NOVEL GENETAC™ THERAPY FOR THE TREATMENT OF FUCHS ENDOTHELIAL
CORNEAL DYSTROPHY TO BE PRESENTED AT ARVO 2022
Source text for Eikon: ID:nGNXhMtdS
Further company coverage: DSGN.O
Recent news on Design Therapeutics
See all newsDesign Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Design Therapeutics Q2 net loss narrower than expected
Brief: Design Therapeutics Q2 Basic EPS USD -0.32
Design Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Design Therapeutics Announces Initiation Of Patient Dosing In Phase 1 Multiple Ascending Dose Trial Of Dt-818 For Myotonic Dystrophy Type-1